## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

a collection of information unless it displays a valid UMB control number			
Confirmation Number	5531		
Application Number	10/823,834		
Filing Date	April 14, 2004		
First Named Inventor	Fennimore		
Group Art Unit	1615		
Examiner Name	C. A. Azpuru		
Attorney Docket Number	CRD5078USNP		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's nitials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/C.A./	BEUTLER, E. "Cladribine (2-chlorodeoxyadenosine)", The Lancet, Vol. 340, p. 952 (October 1992)	
	BREHM, B., et al. "ß-Blockers of the Third Generation Inhibit Endothelin-1	
	Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle	
	and Endothelial Cells", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S-403 (2000)	
	BREHM, B., et al. "Chronically Elevated Endothelin-1 Concentrations Modulate the	
	ß-Adrenergic Receptor System In Vitro and In Vivo", Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000)	
	CARSON, D., et al. "DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death", Experimental Cell Research 164 p. 273-281 (1986)	
	CLOWES and SCHWARTZ, "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", Cir. Res. 56: 139-145 (1985)	
	DEROANNE, C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular endothelial Growth Factor Signaling", Oncogene 21, p. 427-436 (2002)	
	LANG, R., et al. "Effects of Okadaic Acid and ATPyS on Cell Length and CA*" - Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", Br. J. Pharmacol. 104, p. 331-336 (1991)	
	SERRUYS, P. et al. "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial", Circulation of the Journal of the American Heart Association, 88 p. 1588-1601 (1993)	
/C.A.	SERRUYS, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benesten-II Pilot Study', Circulation of the American Heart Association, Volume 93(3) p. 412-422 (1996)	

Examiner Signature	/Carlos Azpuru/	Date Considered	07/08/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I Unique catation designation number. See attached Kinds of U.S. Patient Dozuments. Either Office that issued the document by the wo-letter code (WIPD Standard ST.S.), 4 For Japanese patient documents, the indication of the year of the reging of the Emperor must precede the value number of the patient document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPD Standard ST. 16 if possible. 4 Application is to place a check must here if Emplish inappage Translation is attached.

Burden Nov. Setternet: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief information Officer. U.S. Patent and Tradernack Office. Washington, DC 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrial, VAZ 2713.4450

PTO/SB/08A (06-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

a conection of illiotheron unless it displays.	a valid OMB cortifor number.	
Confirmation Number	5531	
Application Number	10/823,834	
Filing Date	April 14, 2004	
First Named Inventor	Fennimore	
Group Art Unit	1615	
Examiner Name	C. A. Azpuru	
Attorney Docket Number	CRD5078USNP	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
/C.A./	SETO, S., et al. "Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes, J. Clin. Invest. Volume 75 p. 377-383 (1985)	
	WILEY and SONS, "Modern Fluoropolymers" High Performance Polymers for Diverse Applications, Wiley Series in Polymer Science p. 77-90 (1997)	
	WOO, S., et al. "Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors", J. Med. Chem. 45, p. 2877-2885 (2002)	
/c.X./	YOKOI, H., et al. "Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial", JACC Vol. 30, No. 4 p. 855-862 (1997)	

Examiner Signature	/Carlos Azpuru/	Date Considered	07/08/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Burden New Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needed of the individual case. Any comments on the account of time you are required to complete this form should be sent to the Chief Information Office, U. S. Patient and Trademan, Office, Washington, DC 2023.1.

DO NOT SEND FEED OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patients, P.O. Box 1450, Alexandria, VA

22313-1450